human amniotic epithelium-derived stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)

N/A

报告时间: 2026/02/24 20:00:16

基本信息

药物名称human amniotic epithelium-derived stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)

药物别称human amniotic epithelium-derived stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)hAESCs (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)hAECs-dervied stem cells (Icell Biotechnology/The Second Affiliated Hospital of Chongqing Medical University)stem cell therapy (Icell/Chongqing Medical University)

药物类型细胞与基因疗法 > 细胞疗法 > 干细胞疗法 > 上皮干细胞疗法

作用机制干细胞调节剂

靶点更新中

治疗领域 / 适应症移植物抗宿主病子宫疾病卵巢功能早衰 +[5]

全球批准适应症N/A

中国批准适应症N/A

首批国家/区域N/A

首批日期N/A

国家/区域中国大陆

是否复方否

全球最高研发状态临床一期

中国最高研发状态临床一期

原研公司上海赛傲生物技术有限公司

注册分类N/A

研发信息

活跃公司上海赛傲生物技术有限公司重庆医科大学附属第二医院

非活跃公司N/A

活跃适应症移植物抗宿主病子宫疾病卵巢功能早衰 +[5]

非活跃适应症N/A

其他信息

ATC代码N/A